Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background: The skin microbiota influence skin health in several skin diseases and atopic dermatitis (AD). Presence of Staphylococcus have been associated to a sever course of the disease.
Objectives: The aim of the study is to investigate the influence of bacteria, and the skin microbiota on the inflammation and skin barrier. Moreover, dysbiosis in the microbiota, the inflammation profile, the skin barrier damage will be related to objective and patient oriented measures.
Importance: Knowledge of interactions between host defense, skin barrier and bacterial colonizing skin can facilitate development of new prevention and treatment strategies to control microbial impact in skin diseases and eczema.
The role of the skin microbiome in atopic eczema and other skin diseases remains to be investigated. There are reports indicating an association of skin-colonization of Staphylococcus aureus (S. aureus) and the severity of the disease. Skin colonizing pathogens might be important cofactor for persistence of eczema and other skin diseases, as well as the commensal, non-pathogenic, microflora of the skin might have protective effects. The aim of this research project is to investigate the skin microbiome in patients with eczema and other skin diseases and elucidate the relation to skin barrier impairment and severity of the skin disease.
Specifically, we will:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patient with atopic eczema, eczema or other skin diseases |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Skin microbiota | Characterization of skin microbiota are assessed at skin of patients with eczema or skin disease. | At baseline/enrollment through study completion, an average of 1 year. |
| Skin Barrier impairment tewl | measurement of trans epidermal water loss (g/m2h) | At baseline/enrollment through study completion, an average of 1 year. |
| EASI | Eczema area and severity index are assessed (score 0-72) | At baseline/enrollment through study completion, an average of 1 year. |
| Patient oriented outcome measures RECAP | Recap of atopic eczema, RECAP. RECAP is a seven-item questionnaire designed to capture the experience of eczema control in all ages and eczema severities. | At baseline/enrollment through study completion, an average of 1 year. |
| Patient oriented outcome measures POEM | The Patient Oriented Eczema Measure (POEM) is a tool used for monitoring atopic eczema severity. It focuses on the illness as experienced by the patient. | At baseline/enrollment through study completion, an average of 1 year. |
| Patient oriented outcome measures DLQI | The DLQI is designed to measure the health-related quality of life of adult patients suffering from a skin disease. | At baseline/enrollment through study completion, an average of 1 year. |
| Patient oriented outcome measures NRS Itch |
Not provided
Not provided
Inclusion Criteria: Skin diseas, atopic eczema, eczema
-
Exclusion Criteria:
Not provided
Not provided
Not provided
Patints with skin diseases, atopic eczema and eczema. Healthy volonteers.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Skane University Hospital | Lund | Skåne County | 22185 | Sweden |
If confidential
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012871 | Skin Diseases |
| D004485 | Eczema |
| ID | Term |
|---|---|
| D017437 | Skin and Connective Tissue Diseases |
| D003872 | Dermatitis |
| D017443 | Skin Diseases, Eczematous |
Not provided
Not provided
Not provided
Not provided
Not provided
Skin microbiota, skin specimens, blood samples.
The Peak Pruritus Numerical Rating Scale (NRS) is a well-defined, reliable, fit-for-purpose measure to evaluate patient-reported intensity of worst itch in the previous 24 h for adults with moderate-to-severe atopic dermatitis. |
| At baseline/enrollment through study completion, an average of 1 year. |